Candesartan Versus Propranolol for Migraine Prevention

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Migraine Without AuraMigraine With AuraChronic Migraine
Interventions
DRUG

Candesartan

Candesartan cilexitil tablets, 16 mg once daily

DRUG

propranolol

Propranolol hydrochloride capsules 160 mg once daily, slow release formulation

DRUG

placebo

placebo tablets and capsules

Trial Locations (1)

7489

Norwegian National Headache Centre, St. Olavs University Hospital, Trondheim

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

St. Olavs Hospital

OTHER

collaborator

Kragerø Tablettproduksjon as, Norway

UNKNOWN

lead

Norwegian University of Science and Technology

OTHER